3236. [PubMed: 16355210] 51. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N.
3236. [PubMed: 16355210] 51. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis Assays: A Important Overview. Clinical Chemistry. 2003; 49:320. [PubMed: 12507958] 52. Du H, Heur M, Duanmu M, Grabowski GA, Hui DY, Witte DP, Mishra J. Lysosomal acid lipasedeficient mice: depletion of white and brown fat, serious hepatosplenomegaly, and shortened life span. J Lipid Res. 2001; 42:48900. [PubMed: 11290820] 53. Li W, Petrimpol M, Molle KD, Hall MN, Battegay EJ, Humar R. Hypoxia-Induced Endothelial Proliferation Needs Each mTORC1 and mTORC2. Circulation Research. 2007; one hundred:797. [PubMed: 17110594] 54. Laplante M, Sabatini David M. mTOR Signaling in Development Manage and Disease. Cell. 2012; 149:27493. [PubMed: 22500797] 55. Kim GD, Oh J, Jeong LS, Lee SK. Thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, suppresses angiogenesis by regulating PI3K/AKT/mTOR and ERK signaling in endothelial cells. Biochemical and Biophysical Study Communications. 2013; 437:796. [PubMed: 23791876] 56. Du H, Schiavi S, Levine M, Mishra J, Heur M, Grabowski GA. L-type calcium channel Inhibitor site Enzyme therapy for lysosomal acid lipase deficiency within the mouse. Hum Mol Genet. 2001; 10:1639648. [PubMed: 11487567] 57. Du H, Heur M, Witte DP, Ameis D, Grabowski GA. Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice. Hum Gene Ther. 2002; 13:13611372. [PubMed: 12162818] 58. Du H, Cameron TL, Garger SJ, Pogue GP, Hamm LA, White E, Hanley KM, Grabowski GA. Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. J Lipid Res. 2008; 49:1646657. [PubMed: 18413899]NIH-PA CB1 Antagonist review Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptJ Immunol. Author manuscript; accessible in PMC 2015 August 15.Zhao et al.PageNIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptFigure 1. LAL deficiency in ECs results in elevated transendothelial migration of Ly6G+ cells(A) Transwell assay was performed to determine Ly6G+ cells transmigration across the endothelial monolayer formed by lal+/+ or lal-/- ECs. Six hours right after seeding Ly6G+ cells on the EC monolayer, the number of Ly6G+ cells that have migrated for the reduce chamber was counted. Bars represent 250 m. (B) CD4+ T cell transmigration across the endothelial monolayer formed by lal+/+ or lal-/- ECs was examined. Six hours later, the amount of transmigrating CD4+ T cells was counted. (C) Expressions of PECAM-1 and ICAM-2 in ECs had been determined by Western blot evaluation. -actin was employed as handle. Representative blots of four individual experiments had been shown. (D) Transwell assay was performed to identify Ly6G+ cells transmigration across the ECs that had been transfected with PECAM-1 siRNA; (E) Transwell assay was performed to establish Ly6G+ cells transmigration across the ECs that were pre-treated with anti-PECAM-1 neutralizing antibodies or handle IgG; (F) Real-time PCR evaluation of mRNA expression levels of MCP-1, IL-6 and TNF in lal+/+ vs. lal-/- ECs. The relative gene expression was normalized to GAPDH mRNA, and evaluation was performed by the 2-CT technique. (G) Real-time PCR analysis of mRNA expression level of CCR2 in lal+/+ vs. lal-/- Ly6G+ cells. The relative gene expression was normalized to GAPDH mRNA, and analysis was performed by the 2-CT technique. (H) To block chemokines and cytokines, ECs were pre-treated with ten g/mL neutralizing antibody against MCP-1, IL-6, TNF- individually or in mixture, or manage IgG for 1.
